Free tool
FAERS Monitor: Habitrol
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020076 or its brand name (Habitrol, Nicotine). Reports on generic versions are filed under their own applications.
Reports
21,152
Serious
11,446
54% of reports
Hospitalization
4,938
Death reported
1,652
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective2,249
- product adhesion issue2,229
- nicotine dependence1,550
- treatment noncompliance1,549
- product quality issue1,332
- nausea1,289
- overdose1,121
- headache909
- dizziness770
- foetal exposure during pregnancy759
- dyspnoea742
- malaise706
- anxiety673
- pain669
- wrong technique in product usage process648
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 224 |
| 2005 | 209 |
| 2006 | 331 |
| 2007 | 426 |
| 2008 | 324 |
| 2009 | 422 |
| 2010 | 491 |
| 2011 | 555 |
| 2012 | 596 |
| 2013 | 510 |
| 2014 | 559 |
| 2015 | 1,205 |
| 2016 | 1,943 |
| 2017 | 1,505 |
| 2018 | 2,663 |
| 2019 | 1,661 |
| 2020 | 1,433 |
| 2021 | 1,235 |
| 2022 | 950 |
| 2023 | 915 |
| 2024 | 989 |
| 2025 | 1,070 |
| 2026 | 936 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,033,007 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| nicotine dependenceSignal | 1,550 | 247.2 | 234.2 | 304,268 |
| product adhesion issueSignal | 2,229 | 66.1 | 63.5 | 134,152 |
| treatment noncomplianceSignal | 1,549 | 28.9 | 27.6 | 40,688 |
| product quality issueSignal | 1,332 | 9.8 | 9.3 | 10,532 |
| foetal exposure during pregnancySignal | 759 | 9.4 | 8.7 | 5,630 |
| overdoseSignal | 1,121 | 5.2 | 4.9 | 3,806 |
| wrong technique in product usage processSignal | 648 | 3.2 | 3.0 | 977 |
| anxietySignal | 673 | 2.4 | 2.2 | 529 |
| drug ineffective | 2,249 | 1.7 | 1.6 | 687 |
| nausea | 1,289 | 1.6 | 1.5 | 317 |
| malaise | 706 | 1.6 | 1.5 | 162 |
| dizziness | 770 | 1.5 | 1.4 | 147 |
| headache | 909 | 1.4 | 1.4 | 126 |
| dyspnoea | 742 | 1.3 | 1.2 | 54 |
| pain | 669 | 1.1 | 1.0 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.